The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved garadacimab (brand name Andembry) for patients aged 12 years and older with hereditary angioedema (HAE) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback